Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer

  • Torsten O. Nielsen
  • , Joel S. Parker
  • , Samuel Leung
  • , David Voduc
  • , Mark Ebbert
  • , Tammi Vickery
  • , Sherri R. Davies
  • , Jacqueline Snider
  • , Inge J. Stijleman
  • , Jerry Reed
  • , Maggie C.U. Cheang
  • , Elaine R. Mardis
  • , Charles M. Perou
  • , Philip S. Bernard
  • , Matthew J. Ellis

Producción científica: Articlerevisión exhaustiva

706 Citas (Scopus)

Resumen

Purpose: To compare clinical, immunohistochemical (IHC), and gene expression models of prognosis applicable to formalin-fixed, paraffin-embedded blocks in a large series of estrogen receptor (ER)-positive breast cancers from patients uniformly treated with adjuvant tamoxifen. Experimental Design: Quantitative real-time reverse transcription-PCR (qRT-PCR) assays for 50 genes identifying intrinsic breast cancer subtypes were completed on 786 specimens linked to clinical (median follow-up, 11.7 years) and IHC [ER, progesterone receptor (PR), HER2, and Ki67] data. Performance of predefined intrinsic subtype and risk-of-relapse scores was assessed using multivariable Cox models and Kaplan-Meier analysis. Harrell's C-index was used to compare fixed models trained in independent data sets, including proliferation signatures. Results: Despite clinical ER positivity, 10% of cases were assigned to nonluminal subtypes. qRT-PCR signatures for proliferation genes gave more prognostic information than clinical assays for hormone receptors or Ki67. In Cox models incorporating standard prognostic variables, hazard ratios for breast cancer disease-specific survival over the first 5 years of follow-up, relative to the most common luminal A subtype, are 1.99 [95% confidence interval (CI), 1.09-3.64] for luminal B, 3.65 (95% CI, 1.64-8.16) for HER2-enriched subtype, and 17.71 (95% CI, 1.71-183.33) for the basal-like subtype. For node-negative disease, PAM50 qRT-PCR-based risk assignment weighted for tumor size and proliferation identifies a group with >95% 10-year survival without chemotherapy. In node-positive disease, PAM50-based prognostic models were also superior. Conclusion: The PAM50 gene expression test for intrinsic biological subtype can be applied to large series of formalin-fixed, paraffin-embedded breast cancers, and gives more prognostic information than clinical factors and IHC using standard cut points.

Idioma originalEnglish
Páginas (desde-hasta)5222-5232
Número de páginas11
PublicaciónClinical Cancer Research
Volumen16
N.º21
DOI
EstadoPublished - nov 1 2010

Financiación

FinanciadoresNúmero del financiador
National Childhood Cancer Registry – National Cancer InstituteP50CA058223

    ODS de las Naciones Unidas

    Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

    1. Good health and well being
      Good health and well being

    ASJC Scopus subject areas

    • General Medicine

    Huella

    Profundice en los temas de investigación de 'A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer'. En conjunto forman una huella única.

    Citar esto